Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease.

Kahal, H; Abouda, G; Rigby, A S; Coady, A M; Kilpatrick, E S; Atkin, S L

Kahal, H; Abouda, G; Rigby, A S; Coady, A M; Kilpatrick, E S; Atkin, S L.

Affiliation

Kahal H; Academic Endocrinology, Diabetes and Metabolism, Hull York Medical School, Hull, UK; Centre for Cardiovascular and Metabolic Research, Hull York Medical School, Hull, UK.

Clin Endocrinol (Oxf) ; 81(4): 523-8, 2014 Oct.

Article in En | MEDLINE | ID: mdl-24256515

Subject(s)

Glucagon-Like Peptide 1/analogs & derivatives; Liver Cirrhosis/drug therapy; Liver Cirrhosis/metabolism; Non-alcoholic Fatty Liver Disease/metabolism; Obesity/metabolism; Polycystic Ovary Syndrome/metabolism; Adult; Case-Control Studies; Female; Glucagon-Like Peptide 1/therapeutic use; Humans; Liraglutide; Liver Cirrhosis/blood; Non-alcoholic Fatty Liver Disease/blood; Obesity/blood; Polycystic Ovary Syndrome/blood; Triglycerides/blood

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Polycystic Ovary Syndrome / Glucagon-Like Peptide 1 / Non-alcoholic Fatty Liver Disease / Liver Cirrhosis / Obesity Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans Language: En Journal: Clin Endocrinol (Oxf) Year: 2014 Document type: Article Affiliation country: United kingdom Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google